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Abstract: Background: DNA methylation is an epigenetic control mechanism that may be altered by
environmental exposures. We have previously reported that in utero exposure to the mycotoxin and
liver carcinogen aflatoxin B1 from the maternal diet, as measured using biomarkers in the mothers’
blood, was associated with differential DNA methylation in white blood cells of 6-month-old infants
from The Gambia. Methods: Here we examined aflatoxin B1-associated differential DNA methylation
in white blood cells of 24-month-old children from the same population (n = 244), in relation to the
child’s dietary exposure assessed using aflatoxin albumin biomarkers in blood samples collected at 6,
12 and 18 months of age. HM450 BeadChip arrays were used to assess DNA methylation, with data
compared to aflatoxin albumin adduct levels using two approaches; a continuous model comparing
aflatoxin adducts measured in samples collected at 18 months to DNA methylation at 24 months, and
a categorical time-dose model that took into account aflatoxin adduct levels at 6, 12 and 18 months, for
comparison to DNA methylation at 24 months. Results: Geometric mean (95% confidence intervals)
for aflatoxin albumin levels were 3.78 (3.29, 4.34) at 6 months, 25.1 (21.67, 29.13) at 12 months and 49.48
(43.34, 56.49) at 18 months of age. A number of differentially methylated CpG positions and regions
were associated with aflatoxin exposure, some of which affected gene expression. Pathway analysis
highlighted effects on genes involved with with inflammatory, signalling and growth pathways.
Conclusions: This study provides further evidence that exposure to aflatoxin in early childhood may
impact on DNA methylation.
Keywords: aflatoxin B1; aflatoxin albumin adducts; DNA methylation; Gambian children
1. Introduction
Epigenetic alterations such as DNA methylation changes have been proposed as
important mediators of long-term health effects of environmental exposures [1,2]. DNA
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methylation patterns are set during early development, where they participate in the
establishment and maintenance of cell lineages, but these patterns may be modified during
life [3]. Consistent with the role of DNA methylation as the key mechanism for control
of gene expression [4], changes in DNA methylation patterns have been observed with
aberrant transcriptional changes in cancer and other diseases [5–8]. There is increasing
evidence that environmental exposures, including cigarette smoking, heavy metals and
persistent organic pollutants can alter DNA methylation in humans [1,2]. Changes in DNA
methylation during foetal development have been associated with adverse birth outcomes,
with evidence that these changes can also influence disease in later life [9,10], although the
precise underlying mechanism remains poorly understood.
Aflatoxin B1 (AFB1) is a mycotoxin that is highly toxic and carcinogenic [11]. The
Aspergillus species of fungi that produce AFB1 commonly grow on food crops, including
staples such as maize and peanuts, in warm humid climates, leading to frequent con-
tamination of these crops. At particular high risk of exposure to AFB1 are subsistence
farmers in sub-Saharan Africa, where climate conditions, poor storage practices and low
socioeconomic status combine to increase intake of contaminated foods. Numerous studies
using biomarkers of exposure have shown chronic and occasionally very high levels of
AFB1 exposure among rural populations in sub-Saharan Africa [12–16]. Importantly, many
studies have linked this exposure to adverse health outcomes, including liver cancer, acute
liver disease, and child growth impairment [17,18]. AFB1 is known to induce mutagenic
DNA adducts that are likely to be involved in the development and progression of can-
cer [19]. The mechanism for other health effects have not been determined, but we have
previously shown that in utero exposure to aflatoxin, as assessed by levels of aflatoxin-
albumin adducts (AF-alb) in serum of the mothers, was associated with differential DNA
methylation in a number of genes in the white blood cells (WBC) of the infants [20].
In this study, we examined the impact of early-life exposure to aflatoxin on the DNA
methylome patterns, using a new-generation bead-chip arrays with genome coverage. We
established the methylome profiles of young children’s DNA from Gambian children (who
had been naturally exposed to aflatoxin in their diet, as assessed by measuring AF-alb in
serum) at two years of age. Further analyses revealed that exposure to aflatoxin during the
first two years of life is associated with differential DNA methylation in a range of genes
and pathways, some of which directly relate to known health effects of aflatoxin exposure.
2. Results
2.1. Aflatoxin Exposure over Time in Early Life
Characteristics of the children and geometric mean values for AF-alb are given in
Table 1. We observed an increase in median values of AF-alb with time (3.7 pg/mg albumin
at 6 months, 22.7 pg/mg albumin at 12 months and 47.5 pg/mg albumin at 18 months;
Figure 1B), although an increase between 6 and 12 months was not observed in all individ-
uals (Supplementary file S1B).
2.2. DNA Methylation Markers of Aflatoxin Exposure and Associated Biological Pathways:
Continuous Model
In the continuous model, the Q-Q plot (Figure 1C) shows limited inflation (lambda
close to 1.0), giving a low risk of false positives. Seven differentially methylated positions
(DMPs) had a difference in DNA methylation associated with aflatoxin exposure, with
an FDR-adjusted p-value < 0.5 (Figure 1D; Supplementary file S2). The changes in DNA
methylation according to AF-alb continuous values for these DMPs are shown in Figure 1E,
which also shows that there was no difference according to sex of the children.
In addition to these DMPs, there were 509 DMRs showing differences in relation to
continuous AF-alb levels at 18 months (Figure 2A; Supplementary file S3), with a large
proportion of these encompassing at least three CpG sites with a consistent direction of
effect. Ontology analysis of the results (Figure 2B) showed that the DMRs are enriched in
genes associated with acute hepatic failure, as well as others associated with developmental
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disorders including intrauterine growth retardation (Supplementary file S4; e.g., micrope-
nis, short neck and intrauterine growth retardation). In terms of biological mechanisms,
DNA methylation markers associated with aflatoxin exposure were enriched in inflam-
matory pathways (particularly the hypermethylated DMRs; e.g., IL4 signalling), nervous
system signalling (particularly the hypomethylated DMRs; e.g., alpha adrenergic receptor
signalling, EphrinB-EPHB pathway, adrenaline and noradrenaline biosynthesis, and neuro-
transmitter clearance) and signalling events affecting the growth hormone-insulin-obesity
axis (enriched in both hyper- and hypo-methylated DMRs; e.g., leptin insulin overlap,
IGF1R, insulin signalling, regulation of PGC-1a, growth hormone receptor signalling, and
adipocytokine signaling; Figure 2B).









Birth weight (kg) Mean ± SD
3.03 ± 0.38
AF-alb (pg/mg) GM (95% CI)
6 months (n = 230) 3.78 (3.29, 4.34)
12 months (n = 220) 25.1 (21.67, 29.13)
18 months (n = 210) 49.48 (43.34, 56.49)
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Figure 2. (A) DMRs obtained from the AF18 continuous model are represented on the y-axis and
their constituent CpGs on the x-axis. Hyper- and hypo-methylated CpGs in relation to AF levels
are shown in blue and orange circles, respectively, and the size of the circle is proportional to the
effect size (being the regression coefficient). The middle zoomed cluster represents DMRs encom-
passing three or more CpGs showing a 100% consistent direction of effect. (B) Ontology (first row)
and pathway (other rows) analysis using EnrichR was performed on all DMRs (first column) and
then stratified by hyper- and hypo-methylated DMRs (second and third columns, respectively).
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Hyper- and hypo-DMRs were defined as those in which at least 2/3 of the CpGs show a consistent
direction of effect towards hyper- and hypo-methylation, respectively. Results are ranked by p-value
(the most significant being on top), and only the two most significant pathways (p < 0.05) are shown
for each database. ** FDR < 0.05; * FDR < 0.1. More results for Human Phenotype Ontology of All
DMRs are shown in Table S3A as more than two significant (FDR < 0.1) results were obtained. In
ontology analysis, only Human Phenotype Ontology is reported here as it yielded the most significant
results; GO Biological Process did not yield significant ontologies (FDR < 0.1). A detailed report
for the ontology and pathway analyses is available through the following links: All DMRs: https:
//amp.pharm.mssm.edu/Enrichr/enrich?dataset=b4e3a404c15ef001a7c30c1a13e1d249#; Hypometh
DMRs: https://amp.pharm.mssm.edu/Enrichr/enrich?dataset=9357fa44b29ebb8dc326803ebf26925e;
and Hypermeth DMRs: https://amp.pharm.mssm.edu/Enrichr/enrich?dataset=fcbe92f8726688e4
eee8961de6e89d03 (Accessed on 23 March 2020).
2.3. DNA Methylation Markers of Aflatoxin Exposure and Associated Biological Pathways:
Categorical Time-Dose Model
In the categorical analysis, the Q-Q plots also show low inflation, with lambda values
being close to 1.0 (Figure 3A,C,E). The largest number of hits was seen for the recurrent vs.
low exposure model, followed by the recurrent vs. intermittent and intermittent vs. low
models (Figure 3B,D,F), suggesting a time-dose response. The DMPs (FDR < 0.05) of the
recurrent vs. low (Figure 3B) and recurrent vs. intermittent (Figure 3D) exposure models
are further detailed in Supplementary files 5 and 6, respectively. No DMPs (FDR < 0.05)
were obtained in the intermittent vs. low exposure model (Figure 3F). The methylation
levels for each category (low, recurrent and high) are shown in Figure 3G, visualizing the
effect of the time-dose response of exposure on methylation. Some sex-specific effects are
seen for DMPs: in UBQLN2, WIPI2, PRIM2 and HRH3, the effect was only seen in girls,
and in SULF2, boys showed an inverse (though minor) direction of effect relative to girls.
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Figure 3. Categorical time-dose DMP analysis (recurrent, intermittent or low exposure) of aflatoxin
levels over the period of 6, 12 and 18 months postnatally. (A,C,E) Q-Q plots and the genomic inflation
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factor (lambda) of the DMP analyses. (B,D,F) Manhattan plots showing the significant DMPs, being
above the Bonferroni (red) and FDR (blue) lines. Results for the recurrent vs. low, recurrent vs.
intermittent, and intermittent vs. low aflatoxin exposure models are shown in (A–F), respectively.
(G) Scatter plots of the significant DMPs (FDR < 0.05) obtained from the recurrent vs. low exposure
model, highlighting the methylation levels in relation to recurrent (1), intermittent (2) and low (3)
exposures and stratified in (H) by child sex.
There were 714 DMRs obtained in the Recurrent vs. Low AF-alb model (Figure 4;
see also Supplementary file S7). 51 of these encompass at least one CpG with an effect
size ≥ 5% (Supplementary file S8). The top four DMRs are shown here (Figure 4A). The
DMRs in the MIPEPP3 and HLA-DPB1 genes represent the two DMRs with the largest
number of CpGs, each having an effect size ≥ 5%. Among the remaining DMRs that
pass this criterion, those in the CCKBR and LOC494141 genes are shown because they
encompass at least three consecutive CpGs with an effect size ≥ 5%. Except for HLA-DPB1,
the other three DMRs show a time-dose response, with the effect sizes of intermittent
exposure being in between those of the recurrent and low exposures. For HLA-DPB1,
intermittent and recurrent exposures had almost identical methylation levels highlight-
ing a potentially irreversible hypomethylation effect of AF on this gene, relative to low
exposure. Other DMRs with less stringent criteria are shown in Supplementary file S9
(DMRs encompassing at least two consecutive CpG with effect size ≥ 5%, a max of one
CpG being non-unimodally distributed, and 100% consistent direction of effect among its
CpGs that have an effect size ≥ 3%). The 714 DMRs, particularly the hypermethylated
regions, were enriched in genes associated with circulatory and heart development as
well as cardiac-related pathways (Figure 4B; see also Supplementary file S10; e.g., circu-
latory system development, heart development, hypertrophic cardiomyopathy, cardiac
hypertrophic response, and cardiac progenitor differentiation). Similar to the pathways
enriched in DMRs from the continuous AF-alb model, the DMRs for the recurrent vs. low
model were also enriched in nervous system- (particularly the hypomethylated DMRs;
e.g., axon guidance and GABA-R receptor II signalling), inflammatory- (particularly the
hypomethylated DMRs; e.g., IL8- and CXCR1-mediated signalling) and adipose- (enriched
in both hyper- and hypo-methylated DMRs; e.g., genes targeted by miRNAs in adipocytes,
visceral fat deposits and metabolic syndrome, eicosanoid biosynthesis, and regulation of
fat cell differentiation) related pathways. The most enriched ARCHS4 kinase pathway,
LIMK1, associates with both nervous system (stimulate axon outgrowth) and cardiac-
(predisposing to Supravalvular Aortic Stenosis) related pathways (GeneCards) (see also
Supplementary file S11).
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intermittent vs. low exposure models are shown in Tables S5B and S5C, respectively. (B) Ontology
(first row) and pathway (other rows) analysis using EnrichR was performed on all DMRs (first
column) and then stratified by hyper- and hypo-methylated DMRs (second and third columns,
respectively) of the recurrent vs. low exposure model. Hyper- and hypo-DMRs were defined as
those in which at least 2/3 of the CpGs show a consistent direction of effect towards hyper- and
hypo-methylation, respectively. Results are ranked by p-value (the most significant being on top),
and only the two most significant pathways (p < 0.05) are shown for each database. ** FDR < 0.05;
* FDR < 0.1. More results for GO Biological Process of All DMRs, ARCHS4 Kinases Coexp of All
DMRs and ARCHS4 Kinases Coexp of Hypomethylated DMRs are shown in Tables S3B, S3C and
S3D, respectively, as more than two significant (FDR < 0.1) results were obtained. In ontology
analysis, only GO Biological Process is reported here as it yielded the most significant results; Human
Phenotype Ontology did not yield significant ontologies (FDR < 0.1). A detailed report for the




cc2b973eb21009# (Accessed on 4 September 2020).
2.4. Genomic Distribution and Functional Characterization of Identified DNA Methylation
Markers of Aflatoxin Exposure
Figure 5A shows the overlap in hits between the different reported models. Five out
of seven CpGs are common between the DMP and DMR analyses of the AF-alb continuous
model (A vs. E). Eleven out of 16 CpGs are common between the DMP and DMR analyses
of the AF-alb Recurrent vs. Low categorical model (C vs. G). These examples show that
the DMP and DMR analyses are quite consistent in the two major models. DMRs from
the continuous or categorical time-dose models are similarly enriched in CpG islands and
shores and depleted in shelves and open sear regions relative to the HM450 reference set
(Figure 5B). DMRs from either model are also similarly enriched in promoter, 1–5 Kb to
TSS, 5′UTR and first exon regions and depleted from exons, introns and intergenic regions
relative to the 450K reference set. The DNA methylation at certain CpG loci affects RNA
expression of nearby genes (FDR < 0.05), with the direction of effect being positive for some
eQTMs and negative for others (Figure 5C,D). ATP6V1G2 expression was associated with
differential methylation of cg23965019 (HSPA1B gene) in both the continuous (Figure 5C)
and categorical time-dose (Figure 5D) models.
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levels in order to eliminate any potential direct effect of AF on expression.
3. Methods
3.1. Study Population and Blood Sampling
The current work was part of a study on the impact of aflatoxin and child growth,
which was a sub-study embedded within the Early Nutrition and Immune Development
(ENID) trial (ISRCTN49285450). Pregnant mothers were recruited into the ENID trial from
the rural, West Kiang region of The Gambia. Full details of the ENID trial protocol [21] and
aflatoxin and growth sub-study [18] have been described elsewhere.
Samples used in the current DNA methylation study were from 243 children born into
ENID between May 2011 and December 2012. Children were followed up over two years,
with blood samples taken at 6, 12, 18 and 24 months of age. For the purpose of the current
analysis we used serum extracted from samples at 6, 12 and 18 months and WBC extracted
from samples taken at 24 months.
3.2. AF-alb Analysis
The analysis of AF-alb followed the method first described by Chapot and Wild [22].
Albumin was extracted from serum samples, hydrolysed using pronase and purified
with Sep-pak C-18 cartridges (Waters, Milford, MA, USA). AF-alb was quantified using a
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competitive ELISA [22,23] using a rabbit anti aflatoxin-Cl2-BSA polyclonal antibody (a gift
from Christopher Wild, IARC) as the primary antibody. The detection limit (LOD) was 3 pg
AF-lysine equivalents per mg albumin, and each ELISA included three positive and one
negative control samples for quality control. All samples were measured in duplicate for
each ELISA batch and repeated at least two times on separate days to confirm the results.
Results were accepted when values within each ELISA had a %CV below 10% and samples
tested on separate occasions had a %CV below 15%. If samples lay above the linear part of
the standard curve, the ELISA was repeated at a suitable dilution. This ELISA has been
validated for measuring aflatoxin albumin biomarker levels against dietary aflatoxin intake,
and also against an LC-MS for measuring aflatoxin lysine. Whilst the ELISA consistently
gives Af-alb values that are approximately three-fold higher than aflatoxin lysine values
measured by LC-MS the results between methods correlate for the same samples [24].
The AF-alb values are, therefore, suitable for use in analyses to compare variations in
aflatoxin exposure in relation to health outcomes or other variables such as differential
DNA methylation.
3.3. Bisulfite Conversion
Bisulfite conversion was performed using the EZ-96 DNA Methylation kit (Zymo
Research Corporation, Irvine, CA, USA), and its efficiency was tested using PCR primers
that were specific either to bisulfite-converted or to non-modified DNA and spanning the
NBR2 region.
3.4. Genome-Wide Methylation Array
Sample preparation and hybridization to the HM450 BeadChip arrays (Illumina, San
Diego, CA, USA), which covers ~450,000 CpG sites, were performed at the International
Agency for Research on Cancer (IARC). From the 600 ng of bisulfite-converted DNA per
sample, 200 ng was used for hybridization on the array. Each array consisted of 96 samples
distributed equally among 8 chips in a completely randomized manner so that batch
effects (e.g., sample position and intra and inter-variability in arrays and chips) do not
completely confound with biological covariates of interest. The analysis on the bead
array was conducted following the recommended protocols for amplification, labelling,
hybridization and scanning [25].
3.5. DNA Methylome Data Pre-Processing
Data pre-processing and analysis were performed using R/Bioconductor packages
(http://www.bioconductor.org/, accessed on 27 December 2019). Raw data of the samples
constituted of 485,512 CpG probes from the HM450 array and were loaded from IDAT files
and handled in the minfi package [26] to calculate the methylation level at each CpG as the
beta-value (β = intensity of the methylated allele (M)/(intensity of the unmethylated allele
(U) + intensity of the methylated allele (M) + 100)). Data quality was assessed using box
plots for the distribution of methylated and unmethylated signals, unsupervised clustering
showing close agreement between technical replicates, array-wide multi-dimensional
scaling plots and unsupervised clustering to identify sample outliers, and multidimensional
scaling plots clustering samples into two groups representing infant sex. Filtering of
cross-reactive probes (n = 14,549) [27] and low quality probes (n = 1183) (more than
5% missing values per probe) resulted in a total of 469,853 CpGs to analyze. Beta values
were normalized with Functional normalization (Funnorm, minfi R package) that was
shown to perform equally good or outperform existing normalization methods [28]. It
removes unwanted variation by regressing out variability explained by the control probes
present on the array. Finally, we use surrogate variable analysis (SVA) [29] for batch
effect correction and adjustment for latent variables, a choice validated by the findings
of our benchmarking [30]. SVA also increases statistical power by removing (unwanted)
variability through aggregating information at the data level and constraining the data’s
variability to the phenotype of interest [31]. Of 262 samples initially loaded onto the DNA
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methylation array, five data files were missing and one AF-alb result was missing. After
visual inspection of density plots, one sample was removed for displaying an abnormal
distribution. In addition, six samples were replicates and six samples were found to be
mismatched for sex. This left 243 samples for further analysis.
3.6. Assessment of Cell Mixture Distribution
Quantile-normalized data were used to predict WBC subtypes based on a peripheral
blood reference panel [32] using the minfi package [26]. Proportions of six cell types (B,
CD4+ T, CD8+ T, granulocytes, monocytes and NK) were determined. SVA was also used
as a reference-free method to adjust for differences in WBC composition [33].
3.7. Statistical Analysis, Dimension Reduction and Region-Level Methylation Analysis
Methylation beta-values (i.e., the ratio of the methylated probe intensity and the over-
all intensity), ranging from 0 to 1, were used for data plotting and (biological) interpretation.
A zero-centered logarithmic transformation (M-value, calculated as the log2 ratio of the
intensities of methylated probe vs. unmethylated probe) was used for most statistical
analyses since they are more statistically valid, particularly in differential methylation
analysis [34]. M-values were interrogated for association with Af-alb levels by modelling
the study variables and potential confounders together with latent surrogate variables
in a robust linear regression, using the R software. The distribution of Af-alb values at
6, 12 and 18 months was not Gaussian (p-value < 2.2 × 10−16 for all 3 times points) and
we performed a logarithmic transformation obtaining data conforming more closely to
the normal distribution (p-value = 0.07 and 0.002 for time point 12 and 18 months respec-
tively) (Figure S1A). Statistical models for association of AF-alb with DNA methylation
were adjusted (methylation = AF-alb levels + child sex + WBC types + Sample_Plate +
Ethnicity + Season of sample collection), wherein Sample_Plate represents the HM450
batch of 96 samples each (Figure S1C). A dimension reduction approach (DMRcate) was
implemented to reduce the ~450,000 individual sites into clusters of genetically proximal
and correlated CpGs to enhance statistical power [31] and aid biological inferences (as
single CpG sites often have more subtle functional relevance than CpG clusters), as per our
previous work [35,36]. We used the recommended DMRcate proximity-based criteria and
a minimum of two methylation sites per region with a maximum gap of 500 bp. To reduce
the number of false positive results, we controlled for multiple testing using Benjamini
Hochberg (FDR) procedure [37]. Identified differentially methylated regions (DMRs) were
are reported if their FDR-adjusted p-values were < 0.05.
Two approaches to analysis of data were taken (Supplementary files S1C,D). Firstly, the
continuous model assessed the association between DNA methylation and AF-alb levels
from 18 months (at which the highest levels of exposure were observed and which is closest
in time to the sampling of white blood cells for methylation analysis). Secondly, the levels
of AF-alb were categorised depending on time and dose, specifically based on results for
measurements at 6, 12 and 18 months, on whether levels were above or below the median,
and whether this changed between time points. This categorical time-dose model consists
of three categories: “low”, where AF-alb was low at each timepoint; “recurrent”, where
AF-alb was high during the last two time points (12 and 18 months); and “intermittent”,
where AF-alb was low or high at different time points (Supplementary files S1D).
4. Discussion
In this manuscript, we report changes in DNA methylation associated with aflatoxin
exposure in WBC of Gambian children who are naturally exposed to aflatoxin in their
diet. AF-alb is an established biomarker of aflatoxin exposure that reflects dietary intake of
aflatoxin [12,38]. Chronic aflatoxin exposure in this population is known to be high [39],
largely due to the inclusion of home-farmed peanuts as a dietary staple, and the impact of
the exposure on child growth and liver disease has been reported in this population and
others [18,40–42]. We have previously shown that exposure to aflatoxin in utero, as assessed
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by measurement of maternal AF-alb during pregnancy, is associated with differential DNA
methylation in the WBC of Gambian infants at 6 months old [20]. Here, we have observed
changes in DNA methylation in WBC of infants from the same population (but not the
same children) at 2 years old, associated with levels of AF-alb during early life. The
changes in DNA methylation were observed across a number of genes and pathways,
with associations reported according to two methods of modelling the aflatoxin exposure-
using a continuous model of AF-alb at 18 months (six months prior to blood sampling for
epigenetic analysis) and a categorical model that reflects both time and dose response for
aflatoxin exposure from six to eighteen months. In each case, analyses revealed DMPs and
DMRs associated with AF-alb. Reassuringly, there is a notable amount of overlap between
differentially methylated sites and regions across the analytical models.
Most of the associations observed were for small differences in DNA methylation, so
care must be taken in attributing biological significance to the findings. Nevertheless, it is
of interest to consider the genes and pathways in which differential DNA methylation was
observed. In the model using AF-alb as a continuous variable, seven DMPs were observed.
Four of these genes code for enzymes (SPR, an aldo-keto reductase; SESN1, a member
of the sestrin family that play a role in the cellular response to oxidative stress; ME3,
malic enzyme, which catalyzes the oxidative decarboxylation of malate to pyruvate using
either NAD+ or NADP+ as a cofactor; CAPN5, a calcium-dependent cysteine protease
involved in signal transduction in a variety of cellular processes), of which three are
involved in response to oxidative stress. The others are BIRC8, an IAP-like protein 2 that
is involved in pathways in apoptosis signalling and TNF signalling pathways; CBLN2,
which may play a role in induction of synaptogenesis; and MAP7, a microtubule associated
protein predominantly expressed in cells of epithelial origin and thought to be involved in
microtubule dynamics.
A large number of DMRs were obtained (509), of which a large proportion encom-
passed at least three CpG sites, strengthening the reliability of these results. It is of interest
that many DMRs were enriched in genes associated with hepatic failure, as the liver is
the main target organ for the effects of aflatoxin, including acute poisoning and liver
cancer [43]. This also highlights the ability of epigenetic markers to capture the biological
mechanisms by which aflatoxin exposure leads to liver disease. Aflatoxin has also been
associated with child growth impairment in several studies [18,38] and immune system
effects [44]. In our data, aflatoxin-associated DMRs were enriched in inflammatory path-
ways and signalling events affecting the growth hormone-insulin-obesity axis, as well as
Wnt signalling (involved in embryogenesis). Some of the DMRs relate to developmental
disorders associated with reduced growth, such as brachydactyl syndrome, short neck and
intrauterine growth retardation. Indeed, aflatoxin association in utero has been associated
with impaired birthweight and growth in the infant [45]. Other DMRs observed from
our data are in pathways involved in nervous system signalling events, blood clotting
and morphogenesis.
The categorical time-dose model was used to explore whether changes in recurrence
of exposure level over time affected the DNA methylation patterns. The children in Gambia
are largely exclusively breast fed until five to six months of age [46]. During this period
there may be some exposure to aflatoxin in the form of the metabolite aflatoxin M1 excreted
in breast milk, which is an oxidised, and much less toxic metabolite of aflatoxin B1 [47].
Consequently, AF-alb levels tend to be very low in infants at 6 months, increasing with age
as the children eat more family food [48]. This pattern is reflected in our data. However, as
aflatoxin contamination of food is heterogeneous and will vary from family to family over
time, and by season, levels of AF-alb in blood may be high in children at one sampling
point and low at another, or vice versa. This complicates the interpretation of the role of
the exposure in modifying DNA methylation, and it is not clear which time points may
have a greater effect. The categorical time-dose model, based on the categorical split of
AF-alb levels into high vs. low (based on the median value) attempts to take this variation
into consideration. A small number of these DMPs showed sex related differences, but
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in general the results for boys and girls were similar in the continuous and categorical
time-dose models.
The categorical time-dose model for recurrent vs. low AF-alb resulted in over 700 DMRs,
of which 51 involved more than one CpG site with an effect size of more than 5%. Ontology
analysis showed that DMRs were enriched in genes associated with cardiac and circulatory
development. These genes were characterised by hypermethylation, whereas DMRs in
genes from inflammatory and nervous system genes were mainly hypomethylated. When
comparing the results between the models (Figure 5), the fact that the recurrent vs. low
model (with the highest difference in AF-alb) yields a larger number of CpGs (FDR < 0.05)
than the Recurrent vs. Intermittent or the Intermittent vs. Low models, is indicative of
a time-dose response, which is further supported by a time-dose effect size observed for
many of the yielded DMRs.
In our previous paper exploring epigenetic changes in relation to aflatoxin exposure in
The Gambia, we compared DNA methylation in WBC of infants with AF-alb levels in serum
of the mothers during pregnancy. We found differential DNA methylation in 71 DMPs
associated with levels of maternal aflatoxin exposure. Of these, a small number were also
found in this study. PRKAR1B, coding for a regulatory subunit of cAMP-dependent protein
kinase A, was among genes in the DMRs for the Recurrent vs. Low AF-alb model and
was also a DMP in this model. Mutations in the PRKAR1B gene cause neurodegenerative
disorder [49]. Other genes that were DMP hits in the earlier paper that were found from
one of the analytical models in the current study were TGFB1 (encodes a secreted protein
involved in cell growth and proliferation), HAND2 (encodes a transcription factor essential
for cardiac morphogenesis), ZBTB16 (encodes a zinc finger transcription factor involved
in cell cycle progression), TNXB (encodes a extracellular matrix glycoprotein), AGAP3
(encodes an essential component of the NMDA receptor signalling complex) and DNAJB6
(encodes a molecular chaperone involved in protein folding and assembly). Although only
10% of the genes from the earlier paper were hits in this study, it is interesting that these
genes have shown differential DNA methylation in both 6-month-old children associated
with aflatoxin exposure in pregnant mothers and in 24-month-old children, associated with
aflatoxin exposure during early life.
A number of previous studies have reported changes in DNA methylation in relation
to AFB1 treatment of human cells in vitro [50–53]. When primary human hepatocytes were
treated with AFB1, Rieswijk et al. found six genes that showed persistent hypomethylation
associated with up-regulated gene expression. One of these genes, TXNRD1 (encodes an
oxidoreductase) was a DMP in the recurrent vs. low AF-alb model. Wang et al. reported
that increased methylation of the RUNX3 gene was integral to the transformation of AFB1
treated LO2R cells. Methylation of a DMR including this gene was also seen to be associated
with AF-alb in our Recurrent vs. Low AF-alb model. Modulation of the expression of the
DNA methyl transferases, DNMT1 and DNTM3a, is a possible mechanism by which AFB1
may influence DNA methylation, leading to altered gene expression [54].
A limitation of the current study is that data on aflatoxin exposure of these infants
in utero was not available. Our previous study on 6-month-old infants from the same
Gambian population showed that maternal exposure to aflatoxin is associated with differ-
ential DNA methylation in the children, so it is possible that maternal exposure patterns
may have contributed to DNA methylation in these children as well. Exposures at particu-
lar time points, such as in utero, may have a larger effect on DNA methylation changes
induced by AFB1 than at other times. Nevertheless, it is interesting that 10% of genes
with DMPs identified in the earlier study also showed up as affected in this dataset. We
have taken into account several potential confounding factors in our analytical models.
However, there will be other variables that could have impacted on DNA methylation of
which we were not aware, or for which we do not have data. This is one of the reasons why
we additional corrected for potential unknown effects using SVA (see Methods). Despite
this, there is good evidence that aflatoxin B1 exposure in early life does modulate DNA
methylation, and with several genes showing up in previous studies in vitro and in vivo.
Int. J. Mol. Sci. 2021, 22, 8967 15 of 17
The high levels of aflatoxin exposure in children in Gambia reported here and in
other populations in low- and middle-income countries, highlight the need for aflatoxin
reduction strategies, which have been discussed elsewhere [55].
In summary, our results reveal that dietary exposure to aflatoxin B1 during the first
two years of life is associated with differential DNA methylation in a range of genes and
pathways, some of which directly relate to known health effects of aflatoxin exposure. It is
not clear whether the differences in DNA methylation associated with aflatoxin exposure
are biologically significant. There was an apparent time-dose relationship in response and
overlap of hits between analytical models. This provides further insight into potential
mechanisms underlying the impact of exposure to aflatoxin on human health in early life
periods. Further research into the role of DNA methylation on health effects of aflatoxin
is warranted.
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